cagrilintide semaglutide combination phase 3 2024 CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 cagrisema cagrilintide semaglutide phase 3

rather, these represent individual variations in treatment response that merit clinical attention and potential management adjustments

While this study doesnt specifically look at eating disorders, it does suggest that people with eating disorders may be more likely to seek out GLP-1 medications

10.1016/j.arth.2024.05.034 44 ShumnalievaR.KotovG.MonovS

But we dont have a health care system that is structured to do that.

The results suggested that at week 12 after treatment discontinuation, there was no significant difference in weight regain between significant and not significant weight loss subgroup ( P = 0.99) (Additional file 2: Fig